Next Era of Treatment on Obesity and Diabetes from Ozempic to Orforglipron

Bando H

Published on: 2025-08-26

Abstract

As GLP-1RA, semaglutide includes Ozempic for injection, and Rybelsus for oral medicine. Currently, novel oral Orforglipron (LY?3502970) has been investigated for higher clinical efficacy in phase 1-2-3 studies. Orforglipron seems to show clinical effects for 15 pounds weight reduction in average and HbA1c decrease in 1.6%.   As phase 2 trial of multi-center project (n=45), 383 participants were analyzed for 26 weeks. The results were HbA1c -2.1%, -0.43%, -1.10% and weight -10.1kg, -2.2kg, -3.9kg for Orforglipron, placebo, dulaglutide, respectively. By the doses study of 12, 24, 36, 45mg for 36 weeks, weight changes were -9.4% to -14.7%, while placebo -2.3%.